For us, that really refers to our continuing efforts in what we call post-market surveillance. It really applies to all of the products we regulate. One of the previous members referred to problem reports, as they're called, for medical devices. The equivalent on the drug side is reports on adverse drug reactions. We collect those reports, not only Canadian reports but those from around the world. We look at the literature to see what kind of science is developing. We get updated reports from the manufacturers as well. We analyze all of that and determine whether there may be some kind of a signal that would indicate that we need to take regulatory action.
That's basically how we carry out our business. As I'm sure you see, every week we issue warnings, advisories of some kind. We update labels. That's what we do day in, day out in just managing this business. It's no different for these implants.